Experience of treatment of lung cancer patients using paclitaxel and carboplatin

  • Anwar Jusuf Dharmais National Cancer Center Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta
  • Sutji A. Mariono Pertamina Central General Hospital, Jakarta
  • Karmel L. Tambunan Dharmais National Cancer Center Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta
  • A. H. Reksodiputro Dharmais National Cancer Center Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta
  • Noorwati Soetandyo Dharmais National Cancer Center Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta
  • Ronald Hukom Dharmais National Cancer Center Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta
  • Eddy Suratman Dharmais National Cancer Center Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta
  • A. M. Jayusman Dharmais National Cancer Center Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta
Abstract viewed: 703 times
PDF downloaded: 380 times

Abstract

Abstrak Sembilan belas pasien kanker paru jenis karsinoma bukan set kecil stage Jll & JV mendapat kemoterapi dengan paduan paklitaksel dan karboplatin di Rumah Sakit Kanker Dharmais dan Rumah Sakit Pusat Pertamina Jakarta, terdiri dari J4 laki-laki dan 5 perempuan. Diagnosis histologis ialah adenokarsinoma pada 13 pasien, karsinoma skuamosa pada 4 pasien dan karsinoma adenoskuamosa pada J pasien. Empat belas pasien termasuk stage JV, stage llJB terlihat pada 4 pasien dan stage 11/A pada 1 pasien. Paduan obat terdiri dari paklitaksel, dengan dosis 135-200 mg/m2 dan karboplatin 300 mg/m2 atau AUC 6 mg/ml.min, diberikan melalui infus setiap 3 minggu, paling sedikit 3 siklus. Pasien diikuti secara teratur sampai meninggal. Respon objektif berupa respon parsial (partial response) terlihat pada 12 pasien (63%), 2 pasien tidak menunjukkan perubahan (stable disease) dan perburukan terlihat pada 5 orang (26%). Dua pasien masih hidup masing-masing 22 dan 23 bulan setelah kemoterapi dimulai. Masa tahan hidup 1 tahun adalah 58%dan masa tengah tahan hidup ialah 14 bulan. Abstract Nineteen patients with stage 111 & IV nonsmall cell lung cancer were treated with regimen containing paclitaxel and carboplatin at Dharmais National Cancer Center Hospital and Pertamina General Hospital, Jakarta - Indonesia. There were 14 males and 5 females, the histologic diagnosis being adenocarcinoma in 13 patients, squamous carcinoma in 5 patients and adenosquamous carcinoma in J patient. Fourteen patients were in stage IV, 4 had stage 11/B, one had stage fl/A disease. The regimen contains paclitaxel 135-200 mg/m2, combined with carboplatin 300 mg/m2 or AUC 6 mg/ml. min, given every 3 weeks. Those who undenvent at least 3 cycles of chemotherapy were followed up until death. Objective improvement (partial response) was seen in 12 patients or 63%; 2 had stable disease (11%) and 5 had progressive disease (26%). Two patients are still alive at 22 months and 23 months after starting chemotherapy. The one year survival rate was 58%and median survival time was 14 months. Keywords: nonsmall cell carcinoma, chemotherapy, paclitaxel, carboplatin The treatment
Published
2000-01-01
How to Cite
1.
Jusuf A, Mariono SA, Tambunan KL, Reksodiputro AH, Soetandyo N, Hukom R, Suratman E, Jayusman AM. Experience of treatment of lung cancer patients using paclitaxel and carboplatin. Med J Indones [Internet]. 2000Jan.1 [cited 2021Oct.24];9(1):43-8. Available from: https://mji.ui.ac.id/journal/index.php/mji/article/view/650
Section
Medical Journal of Indonesia